Navigation Links
TNFerade(TM) Phase III Data Presented at ASCO
Date:6/1/2009

" then "Webcasts & Data" then "Data Presentations."

About PACT

GenVec's PACT trial is a multi-center, randomized, active, and controlled study of 330 patients designed to evaluate the safety and efficacy of TNFerade plus standard of care versus standard of care alone in patients with locally advanced pancreatic cancer. The next interim analysis is expected to occur after two-thirds of the events (or 184 deaths) have occurred in the trial. Results are expected to be announced in early 2010.

About TNFerade(TM)

TNFerade, which has not yet been approved for use, is an adenovector, or DNA carrier, which contains the gene for tumor necrosis factor-alpha (TNF alpha), an immune system protein with potent and well-documented anti-cancer effects, for direct injection into tumors. After administration, TNFerade stimulates the production of TNF alpha in the tumor. TNFerade has been granted Fast Track product designation by the U.S. Food and Drug Administration (FDA) for its proposed use in the treatment of locally advanced pancreatic cancer. GenVec is developing TNFerade for use in combination with radiation and/or chemotherapy for the treatment of various cancers.

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM), is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at

SOURCE GenVec, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
2. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
3. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
4. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
5. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
6. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
7. Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction
8. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
9. Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
10. BioCis Pharma Starts a Phase I Clinical Trial With a New Cancer Drug
11. Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... UPI ), a medical device company that develops, manufactures ... today reported financial results for the fiscal 2015 third ... the Company,s Urgent ®  PC Neuromodulation System grew 14.5% ... compared to $3.9 million in the third quarter of ...
(Date:1/22/2015)... /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), ... for cardiovascular disease and overall health is pleased to provide ... and its outlook for 2015 from the CEO, Mr. ... We would like to take this opportunity to share with ...
(Date:1/22/2015)... (NASDAQ: TECH ) announced today that it ... Simple Plex platform through its Proteins Platform division under ... the previously acquired CyPlex instrument platform from CyVek. ... technology which integrates an innovatively designed microfluidic cartridge with ...
Breaking Medicine Technology:Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7Bio-Techne Launches Simple Plex Platform 2Bio-Techne Launches Simple Plex Platform 3
... Embryonic Stem Cell Lines for Therapeutic ... ... has,become the first to report, and painstakingly document, the cloning of a,human ... an,adult donor. The study was published online today by the journal "Stem,Cells.", ...
... SAN DIEGO, Jan. 17 Vical Incorporated,(Nasdaq: ... $2.1 million cash payment,from AnGes MG, Inc. for ... Melanoma (AIMM) Phase 3 trial., AnGes is ... under a,previously announced collaborative agreement through a scheduled ...
Cached Medicine Technology:Study Reports Successful Cloning of Human Embryo Using Adult DNA 2Study Reports Successful Cloning of Human Embryo Using Adult DNA 3Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial 2Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial 3
(Date:1/22/2015)... January 22, 2015 A study ... Medicine flagship journal Medicine & Science in Sports ... exercise may help reduce gastrointestinal (GI) problems associated ... , Participants in the double-blind, placebo-controlled study took ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... revenues in the past three years. Today, the business announces ... According to the sales manager of the company, this is ... 2015. This point can be reflected on the discounted wedding ...
(Date:1/22/2015)... Four years since the release of their debut recording Love is ... Avasa & Matthew Love – the duo are pleased to announce ... White Swan Records on February 24, 2015. , THE ROAD offers ... to all of us to walk out of the mire of ...
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and ... relationship in an effort to further promote visibility and adoption ... has long made AMA journals available via its subscription services, ... JAMA Network. , Long known as both a ...
(Date:1/22/2015)... 22, 2015 JJsHouse.com is a famous dress ... the business announces its latest collection of wedding dresses ... most important issue is the wedding dress on your big ... a woman’s life. Every bride wants to find the most ...
Breaking Medicine News(10 mins):Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... are invited to attend and cover the 2008 ... be held March 16-19, 2008, at the Hyatt ... organized by the Centers for Disease Control and ... Council of State and Territorial Epidemiologists, the Association ...
... It seems to plug calcium leaks that cause tiring ... News) -- An experimental drug may help fatigued athletes ... say physiologists at Columbia University Medical Center. , Tests ... regimens, tiny leaks of calcium continuously enter the muscle ...
... Johns Hopkins researchers from the Whiting School of Engineering and the ... on a chip - designed to mimic the chemical complexities of ... cells in the brain work together to form the nervous system. ... story in the February 2008 issue of the British journal Lab ...
... Tribune has published a,feature story on the terrible incidence ... loving dog owners, and treatments and scientific,research under way ... of release.,Morris Animal Foundation (MAF) is cited as leading ... 10 to 20 years. MAF can help provide the,press ...
... (WASHINGTON, February 12, 2008) A new study demonstrates for ... to create functional immune system blood cells, a finding which ... cells as an alternative source of cells for bone marrow ... and immune disorders, who need these transplants for treatment, was ...
... VEGAS, Feb. 12 For years, celebrities and,socialites ... products, including,toothpaste. Now, however, U.S. suburbanites and urban ... local drugstore to enjoy luxurious French oral,care., ... toothpaste in France for more than three,decades, has ...
Cached Medicine News:Health News:2008 International Conference on Emerging Infectious Diseases 2Health News:Muscle Fatigue Drug May Fight Heart Failure 2Health News:'Lab on a chip' mimics brain chemistry 2Health News:A functional immune system can be derived from embryonic stem cells, preliminary study finds 2Health News:A functional immune system can be derived from embryonic stem cells, preliminary study finds 3Health News:A Favorite in France, Elgydium(R) Toothpaste Makes Entrance Into the U.S. Market 2
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
Model C-10 is a four post cervical orthosis which controls flexion, extension, lateral flexion, rotation, and axial motion. Each post may be individually adjusted in height....
Foam Cervical Collar is medium-firm density. Breathable. Deeply anatomically contoured. Natural color, 100% cotton stockinette-covered for comfort. 2" hook and loop closures are another mark of quali...
... Ezy Wrap® Economy Universal ... foam with synthtic white ... reversed for flexion or ... wash, air dry. 3"H.,Universal ...
Medicine Products: